EP0504136A4 - Tolerogenic immunoglobulin-protein conjugates - Google Patents
Tolerogenic immunoglobulin-protein conjugatesInfo
- Publication number
- EP0504136A4 EP0504136A4 EP19900902970 EP90902970A EP0504136A4 EP 0504136 A4 EP0504136 A4 EP 0504136A4 EP 19900902970 EP19900902970 EP 19900902970 EP 90902970 A EP90902970 A EP 90902970A EP 0504136 A4 EP0504136 A4 EP 0504136A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- tolerogenic
- immunoglobulin
- protein conjugates
- conjugates
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1989/005539 WO1991008773A1 (en) | 1989-12-07 | 1989-12-07 | Tolerogenic immunoglobulin-protein conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0504136A1 EP0504136A1 (en) | 1992-09-23 |
| EP0504136A4 true EP0504136A4 (en) | 1994-06-29 |
Family
ID=22215409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP19900902970 Withdrawn EP0504136A4 (en) | 1989-12-07 | 1989-12-07 | Tolerogenic immunoglobulin-protein conjugates |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP0504136A4 (en) |
| JP (1) | JPH05502854A (en) |
| WO (1) | WO1991008773A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| US6086875A (en) * | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
| US6030613A (en) * | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| ATE238668T1 (en) * | 1995-01-17 | 2003-05-15 | Brigham & Womens Hospital | RECEPTOR-SPECIFIC TRANSEPITHELIAL TRANSPORT OF IMMUNOGENS |
| EP1118334A1 (en) | 2000-01-11 | 2001-07-25 | Aventis Behring Gesellschaft mit beschränkter Haftung | Method for the production of conjugates and uses thereof for the prevention and treatment of allergic reactions and autoimmune diseases |
| EP1118335A1 (en) * | 2000-01-11 | 2001-07-25 | Aventis Behring GmbH | Method for the production of conjugates for the treatment of allergic reactions and autoimmune diseases |
| AU2003232751A1 (en) * | 2003-05-12 | 2004-11-26 | Tolerogen, Ltd. | Immunoglobulin conjugates of autoantigens and their use in the prevention of disease |
| WO2011036467A1 (en) * | 2009-09-24 | 2011-03-31 | Russell David Keenan | Products useful in the treatment of haemophilia |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4388441A (en) * | 1977-02-03 | 1983-06-14 | Scripps Clinic & Research Foundation | Induction of immunological tolerance |
| US4550086A (en) * | 1983-02-16 | 1985-10-29 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibodies that recognize human T cells |
| US4650675A (en) * | 1983-08-18 | 1987-03-17 | The Children's Medical Center Corporation | Oligonucleotide conjugates |
-
1989
- 1989-12-07 EP EP19900902970 patent/EP0504136A4/en not_active Withdrawn
- 1989-12-07 WO PCT/US1989/005539 patent/WO1991008773A1/en not_active Application Discontinuation
- 1989-12-07 JP JP90503225A patent/JPH05502854A/en active Pending
Non-Patent Citations (8)
| Title |
|---|
| D.T. GOLAN ET AL.: "NONANTIGENICITY AND IMMUNOLOGIC TOLERANCE: THE ROLE OF THE CARRIER IN THE INDUCTION OF TOLERANCE TO THE HAPTEN", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 134, no. 4, 1971, pages 1046 - 1061 * |
| E.S. RECTOR ET AL.: "A METHOD FOR THE PREPARATION OF PROTEIN-PROTEIN CONJUGATES OF PREDETERMINED COMPOSITION", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 24, no. 1-2, 1978, pages 321 - 336 * |
| H. BOREL ET AL.: "A NOVEL TECHNIQUE TO LINK EITHER PROTEINS OR PEPTIDES TO GAMMAGLOBULIN TO CONSTRUCT TOLEROGENS", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 126, 1990, pages 159 - 168 * |
| I.M. NILSSON ET AL.: "INDUCTION OF SPLIT TOLERANCE AND CLINICAL CURE IN HIGH-RESPONDING HEMOPHILIACS WITH FACTOR IX ANTIBODIES", PROC. NATL. ACAD. SCI., vol. 83, 1986, pages 9169 - 9173 * |
| K.S. TSE ET AL.: "SYNTHESIS OF TOLEROGENIC CONJUGATES FOR SUPPRESSION OF IGE ANTIBODIES TO PROTEIN ALLERGENS", THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 61, no. 3, 1978, pages 180 * |
| See also references of WO9108773A1 * |
| T. BARKAS ET AL.: "EXPERIMENTAL MYASTHENIA GRAVIS IS INHIBITED BY RECEPTOR-ANTIRECEPTOR COMPLEXES", J. CLIN. LAB. IMMUNOL., vol. 7, no. 3, 1982, pages 223 - 227 * |
| Y. BOREL: "NATURAL IMMUNOLOGIC TOLERANCE AND THE CONSTRUCTION OF TOLEROGENS TO TREAT AUTOIMMUNE DISEASES", THERAPY OF AUTOIMMUNE DISEASES.CONCEPTS IMMUNOPATHOL., vol. 7, 1989, BASEL, pages 145 - 161 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH05502854A (en) | 1993-05-20 |
| EP0504136A1 (en) | 1992-09-23 |
| WO1991008773A1 (en) | 1991-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB8903313D0 (en) | Conjugates | |
| ZA879473B (en) | Immunoglubolin conjugates | |
| ZA898434B (en) | Antibody-drug conjugates | |
| GB8908250D0 (en) | Formulations | |
| EP0405242A3 (en) | Vip-analogs ii | |
| GB2239189B (en) | Water-actuated novelty | |
| EP0504136A4 (en) | Tolerogenic immunoglobulin-protein conjugates | |
| GB8919661D0 (en) | Superoxide dismutase-catalase conjugates | |
| AP9000174A0 (en) | Antiparasitical formulations | |
| EP0416363A3 (en) | Modified polyarylenesulfides | |
| ZA89524B (en) | Antibody conjugates | |
| GB2232681B (en) | Nitro-p-phenylenediamine derivatives | |
| GB9003724D0 (en) | Toychest ii | |
| EP0430866A3 (en) | Connection piece | |
| IL92583A0 (en) | Tolerogenic immunoglobulin-protein conjugates | |
| GB9026229D0 (en) | Tolerogenic conjugates for suppressing immune responses | |
| AU5090290A (en) | Tolerogenic immunoglobulin-protein conjugates | |
| NZ238953A (en) | Antibody-superantigen conjugates | |
| IE883489L (en) | Drug-monoclonalantibody conjugates | |
| IE893616L (en) | Antibody-drug conjugates | |
| EP0453452A4 (en) | Vaccine | |
| GB9017729D0 (en) | Conjugates | |
| GB8625461D0 (en) | Conjugates | |
| GB8927373D0 (en) | Tolerogenic conjugates for suppressing immune responses | |
| AU2600688A (en) | Oligonucleotide-polyamide conjugates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19910607 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE ES FR GB IT LI LU NL SE |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 19940506 |
|
| AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE ES FR GB IT LI LU NL SE |
|
| 17Q | First examination report despatched |
Effective date: 19941206 |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BOREL, HALINA Owner name: BOREL, YVES |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: BOREL, HALINA Inventor name: BOREL, YVES |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 19950417 |